FIELD: medicine.
SUBSTANCE: invention refers to biochemistry. What is described is using a recovered antibody or its antigen-binding fragment, which specifically human bind delta-like ligand 4 (hDll4) for producing a medicinal product. The above medicinal product is used in treating a solid malignant tumour in an individual in a synergetic combination with a chemotherapeutic agent specified in a platinum-based chemotherapeutic agent or a pyrimidine analogue, or for suppressing or arresting a solid tumour growth in an individual in a synergetic combination with a chemotherapeutic agent specified in a platinum-based chemotherapeutic agent or a pyrimidine analogue. The human antibody or its antigen-binding fragment contains a heavy chain variable region (HCVR) containing the heavy chain sequences CDR1, CDR2 and CDR3 of SEQ ID NO: 22, 24 and 26, respectively, and a light chain variable region (LCVR) containing the light chain sequences CDR1, CDR2 and CDR3 of SEQ ID NO: 30, 32 and 34, respectively.
EFFECT: higher effectiveness of the method.
12 cl, 5 dwg, 8 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN ANTIBODIES TO DELTA-LIKE HUMAN LIGAND-4 | 2007 |
|
RU2448979C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| METHODS OF TREATING DIABETES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587624C2 |
| ANTI-VEGF/DLL4-IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAINS AND THEIR APPLICATION | 2013 |
|
RU2636043C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2011 |
|
RU2605928C2 |
| METHODS OF TREATING AUTOIMMUNE DISEASES WITH DLL4 ANTAGONISTS | 2011 |
|
RU2587620C2 |
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| VERSIONS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES | 2012 |
|
RU2604814C2 |
